Department of Spinal Surgery, Nanfang Hospital, Southern Medical University, AD: No.1838 North Guangzhou Avenue, Guangzhou, 510515, PR China.
Shanghai Branch, Lilly Suzhou Pharmaceutical Co.Ltd, AD: No. 288 Shimen No.1 Road, Jing'an District, Shanghai, 200041, PR China.
BMC Musculoskelet Disord. 2020 Apr 17;21(1):255. doi: 10.1186/s12891-020-03279-1.
Osteoporotic vertebral compression fractures (OVCF) is a common and often debilitating complication of osteoporosis, leading to significant morbidity and increased mortality. Percutaneous vertebroplasty (PVP) and Percutaneous kyphoplasty (PKP) are recommendable surgical treatments for OVCF.
To evaluate PVP/PKP utilisation and their related direct medical costs for OVCF treatment in China from the payer perspective.
A population-based medical claims database of a metropolitan city in China was analysed from the payer perspective, which included all inpatient claims from 01/01/2015 to 31/12/2017. All vertebral fractures patients that met the eligibility criteria (aged ≥50 years old, having vertebral fracture diagnosis, without unrelated diseases diagnoses such as tumour and scoliosis, received PVP/PKP) were deemed as OVCF patients. Baseline characteristics, surgery rate, length of stay in hospital, time to re-surgery, and costs (including costs per hospitalisation and annual costs) were described. Survival analysis function was used to estimate the re-surgery rate.
Of the 50,686 patients with OVCF identified, 14,527 (28.66%) received a total number of 15,599 records of PVP/PKP surgeries from 2015 to 2017. Mean age was 75 at the first surgery captured in the database analysis period; females accounted for 79.54% of all cases. The median length of surgery stay was 9 days. Cumulative re-surgery rates were 1.22% in 30 days, 2.58% in 90 days, 3.61% in 183 days, 5.42% in 1 year, and 7.95% in 2 years. There was no significant difference in re-surgery rate between PVP and PKP (p = 0.3897). The median time to the re-surgery was 139 days. Mean costs per PVP/PKP-related hospitalisation were 35,906 CNY/5122 USD (34,195 CNY/4878USD for PVP, 44,414 CNY/6336 USD for PKP, p < 0.01). The overall costs of hospitalisation averaged 186.61 million CNY (26.62 million USD) per year in this metropolitan city.
From 2015 to 2017, nearly one-third of OVCF inpatients received PVP/PKP and the re-surgery rate was 7.95%. PVP/PKP procedures for OVCF place a high economic burden for both the healthcare system and patients. Early detection and treatment of patients with osteoporosis are critical in China.
骨质疏松性椎体压缩性骨折(OVCF)是骨质疏松症的一种常见且常导致衰弱的并发症,导致显著的发病率和死亡率增加。经皮椎体成形术(PVP)和经皮椎体后凸成形术(PKP)是 OVCF 的推荐手术治疗方法。
从支付者的角度评估中国 OVCF 治疗中 PVP/PKP 的使用情况及其相关的直接医疗费用。
从支付者的角度分析了中国一个大都市的基于人群的医疗索赔数据库,该数据库包含了 2015 年 1 月 1 日至 2017 年 12 月 31 日的所有住院索赔。所有符合入选标准的椎体骨折患者(年龄≥50 岁,有椎体骨折诊断,无肿瘤和脊柱侧凸等无关疾病诊断,接受 PVP/PKP)被视为 OVCF 患者。描述了基线特征、手术率、住院时间、再次手术时间和费用(包括每次住院费用和年度费用)。生存分析功能用于估计再次手术率。
在 50686 名 OVCF 患者中,有 14527 名(28.66%)在 2015 年至 2017 年期间接受了总共 15599 次 PVP/PKP 手术记录。第一次手术的平均年龄为 75 岁;所有病例中女性占 79.54%。手术住院时间中位数为 9 天。30 天、90 天、183 天、1 年和 2 年的累积再手术率分别为 1.22%、2.58%、3.61%、5.42%和 7.95%。PVP 和 PKP 的再手术率无显著差异(p=0.3897)。再手术的中位时间为 139 天。每次 PVP/PKP 相关住院治疗的平均费用为 35906 元/5122 美元(34195 元/4878 美元用于 PVP,44414 元/6336 美元用于 PKP,p<0.01)。该市每年 PVP/PKP 治疗 OVCF 的总住院费用平均为 1.866.1 亿元人民币(2662 万美元)。
2015 年至 2017 年,近三分之一的 OVCF 住院患者接受了 PVP/PKP 治疗,再手术率为 7.95%。OVCF 的 PVP/PKP 治疗给医疗系统和患者带来了沉重的经济负担。在中国,早期发现和治疗骨质疏松症患者至关重要。